Thetis Pharmaceuticals has received a Fast-Track Small Business Innovation Research (SBIR) Grant from the National Institutes of Health. The grant provides up to $2.3 million to support development of Thetis’ TP-317 candidate as oral therapy for treatment of ulcerative colitis.

Gary Mathias, Co-founder and Chief Executive Officer, commented: “TP-317 offers a fundamentally new approach to IBD treatment based on active resolution of inflammation and the promotion of tissue regeneration without suppressing the immune system.”